MyMD Pharmaceuticals Inc (MYMD)
2.53
-0.20
(-7.33%)
USD |
NASDAQ |
May 09, 16:00
2.57
+0.04
(+1.58%)
After-Hours: 20:00
MyMD Pharmaceuticals Cash from Financing (TTM): 13.07M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 13.07M |
September 30, 2023 | 14.69M |
June 30, 2023 | 20.24M |
March 31, 2023 | 20.24M |
December 31, 2022 | 5.55M |
Date | Value |
---|---|
September 30, 2022 | 6.545M |
June 30, 2022 | 1.190M |
March 31, 2022 | -1.721M |
December 31, 2021 | 0.0735M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-1.721M
Minimum
Mar 2022
20.24M
Maximum
Mar 2023
8.874M
Average
6.545M
Median
Sep 2022
Cash from Financing (TTM) Benchmarks
Acrivon Therapeutics Inc | -1.554M |
Vincerx Pharma Inc | 0.114M |
CEL-SCI Corp | 8.678M |
AIM ImmunoTech Inc | 0.485M |
IGC Pharma Inc | 2.856M |